Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis
Data up to Jan 2025
Total Citations Per Year
Abstract
References (13)
Prediction of Creatinine Clearance from Serum Creatinine
1976 • 15,066 citations
Antiviral effects of phosphonoformate (PFA, foscarnet sodium)
1982 • 339 citations
INHIBITION OF HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE III IN VITRO BY PHOSPHONOFORMATE
1985 • 221 citations
Treatment of Cytomegalovirus Retinitis with Trisodium Phosphonoformate Hexahydrate (Foscarnet)
1988 • 165 citations
Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome
1989 • 155 citations
Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients
1986 • 131 citations
Inhibition of HTLV-III/LAV replication by foscarnet
1985 • 114 citations
Intravenous Foscarnet for the Treatment of Severe Cytomegalovirus Infection in Allograft Recipients
1985 • 106 citations
Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS.
1988 • 80 citations
Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus
1988 • 68 citations
The effect of foscarnet (phosphonoformate) on human immunodeficiency virus isolation, T-cell subsets and lymphocyte function in AIDS patients.
1987 • 44 citations
Acute renal failure induced by foscarnet: 4 cases.
1988 • 43 citations
Treatment of cytomegalovirus pneumonitis with foscarnet (trisodium phosphonoformate) in patients with AIDS
1987 • 35 citations